RISK WARNING: Your capital is at risk. The risks of investing include: illiquidity; lack of dividends; loss of investment; and dilution. You should invest only as part of a diversified portfolio.
Please read FULL risk warning
NATURE POWERED BY SCIENCE Advancing Horse Health and Performance through Science-driven Innovation
A pledge is not a commitment. You will be asked to confirm in the next section.
- The state of the gut is of critical importance to humans and animals alike. It has a direct effect on health and performance. The impact of the microbiome – including bacteria, fungi and viruses – in the gut is now coming under scrutiny. It is these microbiomes in animals that form the scientific focus of THAROS™.
- 2018 will see the market launch of the first THAROS™. product, EquiNectar® horse feed – the culmination of years of research and development. EquiNectar® is the commercialised form of enzyme rich malt extract (ERME), which has been shown to improve the health and performance of racehorses suffering from common digestive problems.
- Contributing to a four-fold increase in prize money during in-feed trials at one leading race yard, EquiNectar® has been described as “a game-changer” by a leading figure in the sector. The original product is being followed up with the development of alternative formats, and with further potential applications in the equine sector and other animals.
The investors and entrepreneurs of Anglo Scientific, strive to build technology led companies underpinned by groundbreaking science that we have either invented ourselves or sourced from gifted third parties. These technologies have the potential to deliver disruptive products to address identified large market opportunities in their areas of expertise: healthcare, security & communications.
Investment Focus: Equity and Debt
About: Envestors is a FCA regulated corporate finance adviser in the UK and operates an international network of sophisticated investors investing an average of £42,000 in high growth unquoted companies seeking £250,000 to £2m in equity funding.
Contact Name: Oliver Woolley
Registered InvestorsOver 1000
Investment through platformOver £100m